Pratia Teams with VirTrial to Become ‘Virtual Trial Capable’
VirTrial has announced an alliance with Pratia, the network of clinical research centers in Europe. All Pratia research centers have completed VirTrial’s Virtual Trial Capable training, making them trained and certified as Virtual Trial Capable and prepared to conduct decentralized clinical trials (DCT).
The training program includes four modules that clinical research professionals complete to demonstrate a level of competence in general telemedicine etiquette and guidelines, as well as how to utilize the VirTrial platform. Participants then receive a Virtual Trial Capable certificate and badge to highlight to sponsors and CROs that they are prepared to conduct hybrid decentralized clinical trials.
“Pratia’s mission is to facilitate access to healthcare to improve the quality of life and the sense of security of our patients. Embracing telehealth technologies that enable a larger patient population to participate supports our goal and we’re proud to be the first network in Europe to offer this benefit to sponsors,” said MaÅgorzata Gerjatowicz-OsmaÅska, Managing Director of Pratia. “Our network is expanding across Europe and we plan to maintain our 100% Virtual Trial Capable status with VirTrial to best serve our patients and pharma sponsors.”
Amanda Rangel, VP of Business Development for VirTrial, remarked, “VirTrial is honored to collaborate with forward-thinking sites like those in the Pratia network that are taking action to move the industry forward and improve patient access to clinical trials. The innovative VirTrial telehealth platform was developed by clinical research professionals and we are committed to continued collaboration with sites and supporting site sustainability in the new era of hybrid decentralized trials.”
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
